VIA
PDLI

Vident Investment Advisory’s PDL BioPharma, Inc. PDLI Stock Holding History

Vident Investment Advisory’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-80,275
Closed -$516K – 1233
2015
Q2 		$516K Buy
80,275
+3,997
+5% +$26.8K 0.07% 485
2015
Q1 		$537K Buy
76,278
+13,586
+22% +$98.4K 0.11% 365
2014
Q4 		$483K Buy
+62,692
New +$496K 0.16% 260

Other funds holding PDLI

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vident Investment Advisory's PDLI Position: Q3 2015 in Review

Vident Investment Advisory sold out of PDL BioPharma, Inc. (PDLI) in Q3 2015, closing a stake of 80,275 shares — an estimated $516K sold.

Vident Investment Advisory first reported a position in PDLI in Q4 2014 and held it in 3 quarters. The position peaked at $537K in Q1 2015. 213 funds tracked by Wall St. Rank hold PDLI as of Q3 2015.

  • Vident Investment Advisory reported no remaining PDL BioPharma, Inc. position as of Q3 2015 after selling out during the quarter.
  • Vident Investment Advisory sold 80,275 PDL BioPharma, Inc. shares in Q3 2015, an estimated $516K.
  • Vident Investment Advisory first reported a position in PDL BioPharma, Inc. in Q4 2014 and held it in 3 quarters.
  • Vident Investment Advisory's PDL BioPharma, Inc. position peaked at $537K in Q1 2015.
  • 213 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2015.

Based on Vident Investment Advisory's 13F filing for Q3 2015, filed 26 Oct 2015.